Effectiveness of infliximab for intralymphatic histiocytosis with rheumatoid arthritis.
Masanobu
M
Sakaguchi
Hiroshi
H
Nagai
Goh
G
Tsuji
Akio
A
Morinobu
Shunichi
S
Kumagai
Chikako
C
Nishigori
D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D005260:Female; D015614:Histiocytosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D042601:Lymphatic Vessels / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab